{"id":"insulin-aspart-30","safety":{"commonSideEffects":[{"rate":null,"effect":"Hypoglycemia"},{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Weight gain"},{"rate":null,"effect":"Lipodystrophy"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Insulin Aspart is a recombinant human insulin analog with a rapid onset of action, designed to mimic the body's natural insulin response to meals. The '30' designation indicates this is a premixed formulation containing 30% insulin aspart and 70% insulin aspart protamine suspension, providing both rapid and intermediate glucose control. It works by binding to insulin receptors on muscle, fat, and liver cells, promoting glucose uptake and storage while suppressing hepatic glucose production.","oneSentence":"Insulin Aspart 30 is a rapid-acting insulin analog that binds to insulin receptors on cells to facilitate glucose uptake and lower blood glucose levels.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:40:10.968Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 1 diabetes mellitus"},{"name":"Type 2 diabetes mellitus"}]},"trialDetails":[{"nctId":"NCT04542148","phase":"PHASE2","title":"Glycemic Control After Antenatal Corticosteroids in Women With Pregestational and Gestational Diabetes","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Alabama at Birmingham","startDate":"2022-02-10","conditions":"Diabetes Mellitus, Type 2, Preterm Birth, Pregnancy, High Risk","enrollment":120},{"nctId":"NCT07387003","phase":"PHASE2","title":"Evaluate the Efficacy and Safety of GZR101-80 Injection in Patients With Type 2 Diabetes","status":"NOT_YET_RECRUITING","sponsor":"Gan & Lee Pharmaceuticals.","startDate":"2026-03-20","conditions":"Type 2 Diabetes (T2DM)","enrollment":300},{"nctId":"NCT06445946","phase":"PHASE4","title":"DECIDE: A Comparative Effectiveness Trial of Metformin Versus Insulin for the Treatment of Gestational Diabetes","status":"RECRUITING","sponsor":"Ohio State University","startDate":"2024-08-01","conditions":"Gestational Diabetes Mellitus, Pregnancy, High Risk","enrollment":1572},{"nctId":"NCT04124302","phase":"PHASE4","title":"The Impact of Two Different Insulin Dose Calculation on Postprandial Glycemia After Mixed Meal.","status":"COMPLETED","sponsor":"Medical University of Warsaw","startDate":"2019-10-01","conditions":"Diabetes Mellitus, Type 1","enrollment":76},{"nctId":"NCT05413369","phase":"PHASE3","title":"iGlarLixi vs IDegAsp in Chinese Participants After OAD(s)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2022-07-07","conditions":"Type 2 Diabetes Mellitus","enrollment":582},{"nctId":"NCT02879409","phase":"NA","title":"HbA1c Variability in Type II Diabetes","status":"ACTIVE_NOT_RECRUITING","sponsor":"Weill Cornell Medical College in Qatar","startDate":"2016-11","conditions":"Diabetes Mellitus Type 2","enrollment":150},{"nctId":"NCT06739473","phase":"PHASE4","title":"Total-body Glucose Utilization in Obesity","status":"RECRUITING","sponsor":"Turku University Hospital","startDate":"2023-01-25","conditions":"Obesity and Overweight","enrollment":60},{"nctId":"NCT04012138","phase":"PHASE4","title":"Insulin Dextrose Infusion vs Nebulized Salbutamol vs Combination of Salbutamol and Insulin Dextrose in Acute Hyperkalemia","status":"RECRUITING","sponsor":"Nantes University Hospital","startDate":"2019-12-20","conditions":"Hyperkalemia","enrollment":525},{"nctId":"NCT03700801","phase":"PHASE4","title":"Study of Efficacy, Weight Control, and Safety in Newly-diagnosed Type 2 Diabetes With Different Antidiabetic Therapy","status":"COMPLETED","sponsor":"Zhujiang Hospital","startDate":"2018-10-01","conditions":"Type 2 Diabetes Mellitus","enrollment":130},{"nctId":"NCT00671008","phase":"","title":"Observational Study of Patients Using NovoMix® 30 or Levemir® for Treatment of Type 1 or Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2007-12","conditions":"Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2","enrollment":400},{"nctId":"NCT00101751","phase":"PHASE4","title":"INITIATE Plus (INITiation of Insulin to Reach A1c TargEt) Study","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2004-10","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":4877},{"nctId":"NCT01486862","phase":"PHASE4","title":"Efficacy of Biphasic Insulin Aspart 30 in Subjects With Type 2 Diabetes Failing on OADs","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2005-10","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":26},{"nctId":"NCT00476437","phase":"PHASE3","title":"Safety and Effect of Biphasic Insulin Aspart 50 in Patients With Type 2 Diabetes Mellitus.","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2007-04","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":81},{"nctId":"NCT02036372","phase":"NA","title":"Perioperative Insulin, GIK or GLP-1 Treatment in Diabetes Mellitus","status":"COMPLETED","sponsor":"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","startDate":"2014-01","conditions":"Diabetes Mellitus Type II","enrollment":150},{"nctId":"NCT05719961","phase":"PHASE1","title":"Bioequivalence Study of INS062 and Pharmacokinetics and Pharmacokinetics Study of Single Injection of HR20014 in Healthy Subjects","status":"UNKNOWN","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2023-01-05","conditions":"Diabetes","enrollment":60},{"nctId":"NCT04141423","phase":"PHASE1","title":"Evaluation of Pharmacokinetics , Safety, Tolerability and Pharmacodynamics of Biocon Insulin Tregopil","status":"TERMINATED","sponsor":"Biocon Limited","startDate":"2019-10-28","conditions":"Type 1 Diabetes Mellitus (T1DM)","enrollment":55},{"nctId":"NCT03359837","phase":"PHASE4","title":"Comparison of Two Treatment Regimens in Patients With Type 2 Diabetes After Short-term Intensive Insulin Therapy","status":"COMPLETED","sponsor":"Sanofi","startDate":"2018-01-20","conditions":"Type 2 Diabetes Mellitus","enrollment":384},{"nctId":"NCT03916601","phase":"PHASE1","title":"Comparison of Exposure and Activity of SAR341402 Mix 70/30 to NovoLog Mix 70/30, NovoMix 30 and SAR341402 Rapid-acting Solution in Patients With Type 1 Diabetes Mellitus","status":"COMPLETED","sponsor":"Sanofi","startDate":"2017-12-13","conditions":"Type 1 Diabetes","enrollment":52},{"nctId":"NCT02688933","phase":"PHASE4","title":"A Study Comparing the Efficacy and Safety of the Morning Injection of Toujeo Versus Lantus in Patients With Type 1 Diabetes Mellitus","status":"COMPLETED","sponsor":"Sanofi","startDate":"2016-05-05","conditions":"Type 1 Diabetes Mellitus","enrollment":638},{"nctId":"NCT01293396","phase":"PHASE4","title":"Comparison of Premixed Insulins Aspart 30, Aspart 70 and Aspart on Postprandial Lipids","status":"COMPLETED","sponsor":"Medical University of Graz","startDate":"2010-06","conditions":"Type 2 Diabetes","enrollment":20},{"nctId":"NCT04739241","phase":"PHASE4","title":"Premixed vs Basal Bolus Insulin Therapy in Older Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Consorci Sanitari Integral","startDate":"2014-01-24","conditions":"Type 2 Diabetes Treated With Insulin","enrollment":60},{"nctId":"NCT04726657","phase":"NA","title":"Comparison of Two Biphasic Insulin Regimens","status":"COMPLETED","sponsor":"Aristotle University Of Thessaloniki","startDate":"2016-01-18","conditions":"Diabetes Mellitus, Type 2","enrollment":36},{"nctId":"NCT03862690","phase":"","title":"A Research Study, Looking at How NovoMix® Works in People With Type 2 Diabetes in Local Clinical Practice in Algeria","status":"WITHDRAWN","sponsor":"Novo Nordisk A/S","startDate":"2020-05-28","conditions":"Diabetes Mellitus, Type 2","enrollment":""},{"nctId":"NCT03816761","phase":"PHASE2","title":"Research Study to Look at Fast-acting Insulin Aspart With the Insulin Pump System 'iLet™' in Adults With Type 1 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2019-02-25","conditions":"Diabetes Mellitus, Type 1","enrollment":24},{"nctId":"NCT02846831","phase":"PHASE2","title":"Closed-loop Control of Glucose Levels (Artificial Pancreas) for 12 Days in Adults With Type 1 Diabetes","status":"COMPLETED","sponsor":"Institut de Recherches Cliniques de Montreal","startDate":"2019-01-24","conditions":"Type 1 Diabetes","enrollment":36},{"nctId":"NCT04226105","phase":"PHASE3","title":"Efficacy and Safety of GP40081 Сompared to NovoMix® 30 FlexPen® in Type 2 Diabetes Mellitus Patients","status":"UNKNOWN","sponsor":"Geropharm","startDate":"2020-01-20","conditions":"Diabetes Mellitus, Type 2, Diabetes Mellitus","enrollment":264},{"nctId":"NCT00821795","phase":"PHASE4","title":"Veterans Inpatient Insulin Study and Transition to Outpatient Therapy","status":"COMPLETED","sponsor":"Dennis G. Karounos, M.D.","startDate":"2009-03-11","conditions":"Type 2 Diabetes Mellitus","enrollment":120},{"nctId":"NCT02814123","phase":"PHASE2","title":"Effect of Basal-Bolus Closed-Loop Co-Administration of Insulin and Pramlintide on Improving the Glycemic Control in Type 1 Diabetes","status":"COMPLETED","sponsor":"McGill University","startDate":"2017-01-13","conditions":"Diabetes Mellitus, Type 1","enrollment":28},{"nctId":"NCT02556918","phase":"PHASE4","title":"Sitagliptin for Hyperglycemia in Patients With T2DM Undergoing Cardiac Surgery","status":"COMPLETED","sponsor":"Emory University","startDate":"2016-01","conditions":"Hyperglycemia","enrollment":202},{"nctId":"NCT04184492","phase":"NA","title":"A Study to Compare Pharmacokinetics and Pharmacodynamics of GP-40081 to NovoMix® 30 Penfill® in Healthy Subjects","status":"COMPLETED","sponsor":"Geropharm","startDate":"2019-04-15","conditions":"Clamp Study","enrollment":34},{"nctId":"NCT02987751","phase":"PHASE4","title":"A Study on Comparison of Glargine Plus Glulisine With Premixed Insulin in Type 2 Diabetes Patients","status":"COMPLETED","sponsor":"India Diabetes Research Foundation & Dr. A. Ramachandran's Diabetes Hospitals","startDate":"2016-12-29","conditions":"Type2 Diabetes","enrollment":200},{"nctId":"NCT02846857","phase":"PHASE2","title":"Closed-loop Control of Glucose Levels (Artificial Pancreas) for 15 Weeks in Adolescents and Adults With Type 1 Diabetes","status":"WITHDRAWN","sponsor":"Institut de Recherches Cliniques de Montreal","startDate":"","conditions":"Type 1 Diabetes","enrollment":""},{"nctId":"NCT02582242","phase":"PHASE4","title":"Comparing Efficacy and Safety of Thrice Daily Versus Twice Daily NovoMix® 30 (Biphasic Insulin Aspart 30) in Subjects With Type 2 Diabetes Inadequately Controlled With Basal Insulin","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2015-10-19","conditions":"Diabetes, Type 2 Diabetes Mellitus","enrollment":437},{"nctId":"NCT02762578","phase":"PHASE3","title":"Comparing Efficacy and Safety of Insulin Degludec/Insulin Aspart and BIAsp 30 in Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2016-05-03","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":543},{"nctId":"NCT01513590","phase":"PHASE3","title":"A Trial Comparing Efficacy and Safety of Insulin Degludec/Insulin Aspart and BIAsp 30 in Insulin naïve Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2012-01-16","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":394},{"nctId":"NCT02855307","phase":"PHASE2","title":"Closed-loop Control of Glucose Levels (Artificial Pancreas) During Postprandial Exercise in Adults With Type 1 Diabetes","status":"COMPLETED","sponsor":"Institut de Recherches Cliniques de Montreal","startDate":"2016-09","conditions":"Type 1 Diabetes","enrollment":37},{"nctId":"NCT02453685","phase":"PHASE4","title":"A Study to Compare Insulin Intensification of Biphasic Insulin Aspart 30 and Insulin Analogues (Insulin Glargine and Insulin Aspart) in Insulin naïve Type 2 Diabetic Patients","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2015-08-31","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":335},{"nctId":"NCT00505882","phase":"PHASE4","title":"Efficacy of Pramlintide on Prevention of Weight Gain Early Onset of Type 1 Diabetes","status":"WITHDRAWN","sponsor":"University of Texas Southwestern Medical Center","startDate":"2007-07","conditions":"Type 1 Diabetes","enrollment":""},{"nctId":"NCT01059812","phase":"PHASE3","title":"A Pan Asian Trial Comparing Efficacy and Safety of NN5401 and Biphasic Insulin Aspart 30 in Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2010-02-01","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":424},{"nctId":"NCT01009580","phase":"PHASE3","title":"Comparison of NN5401 With Biphasic Insulin Aspart 30 in Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2009-11-05","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":447},{"nctId":"NCT02467920","phase":"PHASE4","title":"Efficacy and Safety of Basal Insulin Glargine Combination With Exenatide Bid vs Aspart30 in T2DM","status":"COMPLETED","sponsor":"Huazhong University of Science and Technology","startDate":"2015-08","conditions":"Type 2 Diabetes Mellitus","enrollment":349},{"nctId":"NCT02449603","phase":"PHASE4","title":"Comparison of Exenatide vs. Biphasic Insulin Aspart 30 on Glucose Variability in Type 2 Diabetes","status":"COMPLETED","sponsor":"Xijing Hospital","startDate":"2015-11","conditions":"Type 2 Diabetes Mellitus","enrollment":150},{"nctId":"NCT02648217","phase":"PHASE3","title":"Comparing Efficacy and Safety of Insulin Degludec/Insulin Aspart Twice Daily and Biphasic Insulin Aspart Twice Daily in Subjects With Type 2 Diabetes Mellitus Before, During and After Ramadan","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2016-01-04","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":263},{"nctId":"NCT03374774","phase":"","title":"A Non-interventional Study of Ability and Willingness to Pay for BIAsp 30 in a Real World Population With Type 2 Diabetes Mellitus (T2DM)","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2017-11-13","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":516},{"nctId":"NCT02219750","phase":"PHASE4","title":"Comparison of Premixed Insulin With Basal-plus Insulin in Type 2 Diabetes Patients","status":"COMPLETED","sponsor":"Mackay Memorial Hospital","startDate":"2013-08","conditions":"Diabetes","enrollment":181},{"nctId":"NCT02741687","phase":"PHASE4","title":"Sitagliptin in Non-Diabetic Patients Undergoing General Surgery","status":"COMPLETED","sponsor":"Emory University","startDate":"2016-06","conditions":"Hyperglycemia","enrollment":80},{"nctId":"NCT03335501","phase":"PHASE2","title":"Comparison of the Efficacy of Rapid-acting Aspart and Faster Acting Aspart Within the Context of Single-hormone Closed-loop Strategy at Regulating Postprandial Glucose Levels","status":"WITHDRAWN","sponsor":"Institut de Recherches Cliniques de Montreal","startDate":"2018-04-01","conditions":"Type 1 Diabetes Mellitus","enrollment":""},{"nctId":"NCT02443402","phase":"PHASE4","title":"Sitagliptin in Non-Diabetic Patients Undergoing Cardiac Surgery","status":"COMPLETED","sponsor":"Emory University","startDate":"2016-01","conditions":"Coronary Artery Disease","enrollment":68},{"nctId":"NCT02488616","phase":"PHASE2","title":"Closed-loop Control of Glucose Levels (Artificial Pancreas) for 5 Days in Adults With Type 1 Diabetes","status":"WITHDRAWN","sponsor":"Institut de Recherches Cliniques de Montreal","startDate":"2018-03","conditions":"Type 1 Diabetes","enrollment":""},{"nctId":"NCT02933645","phase":"NA","title":"Effects of Intranasal Insulin Administration on Tissue Specific Insulin Sensitivity","status":"COMPLETED","sponsor":"Turku University Hospital","startDate":"2016-04","conditions":"Insulin Resistance","enrollment":10},{"nctId":"NCT00659282","phase":"","title":"Observational Study of Safety and Effectiveness of NovoMix® 30 for the Treatment of Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2006-09-11","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":57610},{"nctId":"NCT00232583","phase":"NA","title":"Preservation of Beta-cell Function in Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"University of Texas Southwestern Medical Center","startDate":"2003-11","conditions":"Type 2 Diabetes Mellitus","enrollment":58},{"nctId":"NCT03212950","phase":"NA","title":"Closed-Loop With Faster Aspart in Young Adults With Type 1 Diabetes","status":"COMPLETED","sponsor":"University of Ljubljana, Faculty of Medicine","startDate":"2017-07-10","conditions":"Type 1 Diabetes Mellitus","enrollment":20},{"nctId":"NCT01999322","phase":"PHASE3","title":"A Trial Evaluating Compatibility and Safety of FIAsp and Insulin Aspart With an External Continuous Subcutaneous Insulin Infusion System in Adult Subjects With Type 1 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2013-11-19","conditions":"Diabetes, Diabetes Mellitus, Type 1","enrollment":37},{"nctId":"NCT01538511","phase":"PHASE1","title":"Insulin Profile of Biphasic Insulin Aspart 70 to That of Biphasic Insulin Aspart 30 in Healthy Volunteers","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2006-06-05","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":59},{"nctId":"NCT01589653","phase":"PHASE4","title":"Comparing Patient-adjusted Versus Physician-adjusted Titration of BIAsp 30 Combined With Metformin in Type 2 Diabetes Patients","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2012-05-26","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":155},{"nctId":"NCT00605020","phase":"PHASE3","title":"Efficacy and Safety of Insulin Detemir in Combination With Insulin Aspart and Biphasic Insulin Aspart 30 in Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2003-12-02","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":719},{"nctId":"NCT00614055","phase":"PHASE2","title":"Comparison of Two NN5401 Formulations Versus Insulin Glargine, All in Combination With Metformin in Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2008-01","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":178},{"nctId":"NCT00613951","phase":"PHASE2","title":"Comparison of Two NN5401 Formulations Versus Biphasic Insulin Aspart 30, All in Combination With Metformin in Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2008-01","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":182},{"nctId":"NCT00184600","phase":"PHASE3","title":"Comparison of Insulin Detemir, Insulin Aspart and Biphasic Insulin Aspart 30 With OAD Treatment in Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2004-11","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":708},{"nctId":"NCT00564668","phase":"PHASE3","title":"Comparison of Biphasic Insulin Aspart Produced by the NN2000 Process to Current Process to in Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2004-06-19","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":126},{"nctId":"NCT01620450","phase":"PHASE1","title":"Comparison of Insulin Aspart Produced by Current Process and the NN2000 Process in Healthy Japanese","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2004-11-20","conditions":"Diabetes, Healthy","enrollment":34},{"nctId":"NCT01650129","phase":"PHASE3","title":"Safety and Efficacy of Biphasic Insulin Aspart 50 in Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2000-12-13","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":83},{"nctId":"NCT01467401","phase":"PHASE4","title":"Efficacy and Safety of NovoMix® 30 in Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2002-08-19","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":292},{"nctId":"NCT01523041","phase":"PHASE1","title":"Comparison of Two Formulations of Biphasic Insulin Aspart 70","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"1999-11-03","conditions":"Diabetes, Healthy","enrollment":24},{"nctId":"NCT01704378","phase":"PHASE4","title":"Efficacy and Safety of Biphasic Insulin Aspart 30 FlexPen™ in Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2001-04-18","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":89},{"nctId":"NCT00184626","phase":"PHASE4","title":"Comparison of Insulin Glargine Versus Biphasic Insulin Aspart 30/70 or Biphasic Insulin Aspart 30/70 in Combination With Metformin in Subjects With Type 2 Diabetes.","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2004-09-10","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":97},{"nctId":"NCT01527539","phase":"PHASE3","title":"Long Term Safety and Efficacy of Biphasic Insulin Aspart 30 in Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2001-11-23","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":25},{"nctId":"NCT00617565","phase":"PHASE3","title":"Efficacy and Safety of Biphasic Insulin Aspart 30 in Type 1 or 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2003-07-08","conditions":"Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2","enrollment":219},{"nctId":"NCT01519674","phase":"PHASE4","title":"Treatment Intensification With Biphasic Insulin Aspart 30 in Subjects With Type 2 Diabetes Inadequately Controlled on Sitagliptin and Metformin","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2012-06","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":582},{"nctId":"NCT01527565","phase":"PHASE1","title":"Bioequivalence of Two Formulations of Biphasic Insulin Aspart 70 in Healthy Male Subjects","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2003-01-20","conditions":"Diabetes, Healthy","enrollment":30},{"nctId":"NCT01536626","phase":"","title":"Switch From Premixed Human Insulin to Biphasic Insulin Aspart in the Netherlands","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2006-06-09","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":211},{"nctId":"NCT00592969","phase":"PHASE4","title":"Efficacy and Safety of Metformin Plus Biphasic Insulin Aspart 30 in Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2003-12-03","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":164},{"nctId":"NCT01427920","phase":"PHASE4","title":"Comparison of Biphasic Insulin Aspart 30 Individually Adjusted by the Subject and the Trial Physician, Both Combined With Metformin in Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2011-09","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":348},{"nctId":"NCT01697631","phase":"PHASE4","title":"Glycemic Control of Biphasic Insulin Aspart 30 in Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2002-07-22","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":131},{"nctId":"NCT00791895","phase":"PHASE4","title":"Efficacy of Biphasic Insulin Aspart 30 in Type 2 Diabetics Failing on OADs","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2003-06-26","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":102},{"nctId":"NCT01618214","phase":"PHASE4","title":"Comparison of Subject-driven Titration of Biphasic Insulin Aspart (BIAsp) 30 Twice Daily Versus Investigator-driven Titration of BIAsp 30 Twice Daily Both in Combination With Oral Antidiabetic Drugs in Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2012-06","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":344},{"nctId":"NCT01123980","phase":"PHASE4","title":"Comparison of the Blood Sugar Lowering Effect of Biphasic Insulin Aspart 30 and Insulin Glargine Both Combined With Metformin and Glimepiride in Chinese and Japanese Subjects With Type 2 Diabetes New to Insulin Treatment","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2010-05","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":521},{"nctId":"NCT01486381","phase":"PHASE3","title":"Long Term Safety of Biphasic Insulin Aspart 30 in Juveniles With Type 1 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2002-03-20","conditions":"Diabetes, Diabetes Mellitus, Type 1","enrollment":22},{"nctId":"NCT01467375","phase":"PHASE3","title":"Long Term Safety and Efficacy of Biphasic Insulin Aspart 30 in Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2001-01-08","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":89},{"nctId":"NCT00469092","phase":"PHASE4","title":"Comparison of Biphasic Insulin Aspart 30 Versus Insulin Glargine Both in Combination With Metformin and Glimepiride in Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2007-05","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":480},{"nctId":"NCT01467141","phase":"PHASE4","title":"Safety and Efficacy of Insulin Aspart in Children With Type 1 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2002-06-19","conditions":"Diabetes, Diabetes Mellitus, Type 1","enrollment":26},{"nctId":"NCT01174303","phase":"PHASE1","title":"A Trial Investigating the Exposure of NN5401 in Young Adults and Elderly Subjects With Type 1 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2010-08","conditions":"Diabetes, Diabetes Mellitus, Type 1","enrollment":28},{"nctId":"NCT01051102","phase":"PHASE1","title":"Effect of NN5401 in Japanese Subjects With Type 1 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2010-01","conditions":"Diabetes, Diabetes Mellitus, Type 1","enrollment":21},{"nctId":"NCT00993096","phase":"PHASE1","title":"Investigation of the Response Relationship of NN5401 in Type 1 Diabetics","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2009-09","conditions":"Diabetes, Diabetes Mellitus, Type 1","enrollment":33},{"nctId":"NCT00842361","phase":"PHASE2","title":"Comparison of NN5401 Versus Biphasic Insulin Aspart 30 on a Twice Daily Regimen in Subjects With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2009-01","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":66},{"nctId":"NCT01542424","phase":"","title":"An Observational Study in Patients Using NovoMix® 30 or Levemir® for Treatment of Type 1 or Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2006-03","conditions":"Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2","enrollment":1889},{"nctId":"NCT00869908","phase":"","title":"Observational Study on the Effect of NovoMix® 30, Levemir® or NovoRapid® (Alone or Combined) in Type 2 Diabetics Previously Treated With Anti-diabetic Medication","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2008-11","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":66726},{"nctId":"NCT01068652","phase":"PHASE4","title":"Effect of Different Insulin Administrations, All in Combination With Metformin, on Glycaemic Control in Subjects With Type 2 Diabetes Inadequately Controlled by Oral Anti-diabetic Drugs","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2010-03","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":403},{"nctId":"NCT03018665","phase":"PHASE4","title":"A Study of the Effect of Glucagon-like Peptide 1(GLP-1) Receptor Agonist in Combination With Metformin Therapy on Diabetes Remission in Subjects With Newly Diagnosed Type 2 Diabetes Who Are Overweight or Obese","status":"UNKNOWN","sponsor":"The First Hospital of Jilin University","startDate":"2017-02","conditions":"Diabetes Mellitus, Type 2","enrollment":200},{"nctId":"NCT00097877","phase":"PHASE3","title":"Comparison of Biphasic Insulin Aspart 70/30 Versus Insulin Glargine in Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2005-01","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":293},{"nctId":"NCT00775736","phase":"","title":"Observational Study Evaluating the Safety of NovoMix® in Type 2 Diabetes Patients Previously Treated With a Human Premix Insulin","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2008-10","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":611},{"nctId":"NCT00605111","phase":"PHASE4","title":"Efficacy and Safety of Biphasic Insulin Aspart 30 in Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2003-12","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":193},{"nctId":"NCT00097279","phase":"PHASE3","title":"Comparison of Biphasic Insulin Aspart 70/30 With Anti-Diabetic Drugs in Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2004-08","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":230},{"nctId":"NCT01536639","phase":"","title":"Physiological Concept of Insulin Therapy in Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2006-01","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":454},{"nctId":"NCT00598793","phase":"PHASE3","title":"Biphasic Insulin Aspart 30 in Type 2 Diabetes Failing OAD Therapy","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2002-11","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":242},{"nctId":"NCT00657319","phase":"","title":"Glycaemic Control and Quality of Care in Type 2 Diabetes on NovoMix® 30 Previously Treated With Mixtard® Insulins","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2007-10","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":3495},{"nctId":"NCT00665093","phase":"","title":"Observational Study of Patients Using NovoMix® 30 or Levemir® for Treatment of Type 1 or Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2007-05","conditions":"Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2","enrollment":1569},{"nctId":"NCT00696995","phase":"","title":"An Observational Study of Type 2 Diabetes in Patients Starting on NovoMix® 30 Treatment","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2007-01","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":509},{"nctId":"NCT01527656","phase":"PHASE1","title":"Bioequivalence of Two Formulations of Biphasic Insulin Aspart 70 in Healthy Subjects","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2003-12","conditions":"Diabetes, Healthy","enrollment":40}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":207,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Novomix 30"],"phase":"marketed","status":"active","brandName":"Insulin Aspart 30","genericName":"Insulin Aspart 30","companyName":"Medical University of Graz","companyId":"medical-university-of-graz","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Insulin Aspart 30 is a rapid-acting insulin analog that binds to insulin receptors on cells to facilitate glucose uptake and utilization for energy and storage. Used for Type 1 diabetes mellitus, Type 2 diabetes mellitus.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}